The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Regeneron Pharmaceuticals Inc

Nasdaq: REGN
Last

(U.S.) $339.48

Today's change-17.66 -4.94%
Updated June 24 4:00 PM EDT. Delayed by at least 15 minutes.
 

Regeneron Pharmaceuticals Inc

Nasdaq: REGN
Last

(U.S.) $339.48

Today's change-17.66 -4.94%
Updated June 24 4:00 PM EDT. Delayed by at least 15 minutes.

Regeneron Pharmaceuticals Inc down (U.S.)$17.66

Regeneron Pharmaceuticals Inc closed sharply lower Friday, dropping (U.S.)$17.66 or 4.94% to (U.S.)$339.48. Over the last five days, shares have lost 4.16% and are down 37.47% for the last year to date. This security has underperformed the S&P 500 by 30.91% during the last year.

Key company metrics

  • Open(U.S.) $341.70
  • Previous close(U.S.) $357.14
  • High(U.S.) $350.09
  • Low(U.S.) $338.69
  • Bid / Ask(U.S.) $325.01 / (U.S.) $339.48
  • YTD % change-37.47%
  • Volume1,288,269
  • Average volume (10-day)889,587
  • Average volume (1-month)936,732
  • Average volume (3-month)923,204
  • 52-week range(U.S.) $338.69 to (U.S.) $605.93
  • Beta1.07
  • Trailing P/E53.92×
  • P/E 1 year forward31.84×
  • Forward PEG1.69×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $6.30
Updated June 24 4:00 PM EDT. Delayed by at least 15 minutes.
S&P TSX1.69%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2016Q4/2015Q3/2015Q2/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015
Revenue1,2011,0981,137999
Total other revenue--------
Total revenue1,2011,0981,137999
Gross profit1,0899871,028910
Total cost of revenue11211110989
Total operating expense872869745670
Selling / general / administrative290295210175
Research & development470461426390
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--2016
Other operating expenses, total--------
Operating income329229392329
Interest income (expense), net non-operating---4-2-3
Gain (loss) on sale of assets--------
Other--------
Income before tax330227393328
Income after tax166155210195
Income tax, total16472183133
Net income166155210195
Total adjustments to net income--------
Net income before extra. items166155210195
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items166155210195
Inc. avail. to common incl. extra. items166155210195
Diluted net income166155210195
Dilution adjustment--0----
Diluted weighted average shares114115116115
Diluted EPS excluding extraordinary itemsvalue per share1.451.341.811.69
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share1.451.351.811.77